Tag: Abbott

Abbott’s In-Development Fully Implantable Heart Pump System Earns FDA’s Breakthrough Device Designation

ABBOTT PARK, Ill., Feb. 4, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development Fully Implantable Left Ventricular Assist System (FILVAS). The FDA launched the Breakthrough Devices Program in 2018 to help expedite the development and review […]

ABBOTT ANNOUNCES FIRST-OF-ITS-KIND TRIAL TO ASSESS NEW THERAPY OPTION FOR PEOPLE AT RISK OF STROKE

– The CATALYST trial will examine Abbott’s Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation ABBOTT PARK, Ill., Feb. 3, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration […]

ABBOTT’S TENDYNE™ DEVICE RECEIVES WORLD’S FIRST CE MARK FOR TRANSCATHETER MITRAL VALVE IMPLANTATION

– First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option – Tendyne valve provides relief from heart failure symptoms and quality-of-life improvement in high-surgical-risk patients – Together with MitraClip™, Tendyne expands Abbott’s market-leading portfolio of innovative minimally invasive mitral valve solutions […]

Abbott Reports Fourth-Quarter 2019 Results; Announces Strong Forecast for 2020

– Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent – Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent – Several businesses achieved double-digit sales growth – Forecast reflects continued top-tier sales and earnings growth […]

PREDICT-LAA Trial Enrolls First Patient

GENT, Belgium–(BUSINESS WIRE)–FEops, a leader in personalized predictive planning for structural heart interventions, is proud to announce that today the first patient has been enrolled in the physician-initiated PREDICT-LAA trial. The trial is led by Righshospitalet (Copenhagen, Denmark) and aims to assess whether the use of FEops HEARTguide™ computer simulations based on cardiac CT-imaging can contribute to […]

Abbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients

– New clinical trial will assess first-of-its-kind MitraClip™ transcatheter mitral valve repair against current standard of care surgery in a new, expanded patient population – If successful, the REPAIR MR study has potential to expand MitraClip’s current indication (patients at prohibitive risk for surgery) to also include patients at moderate […]

FDA Approves Less Invasive Surgical Approach for Abbott’s Heart Pump to Help Patients Avoid Open Heart Surgery

– For people battling advanced heart failure, Abbott’s HeartMate 3 heart pump can now be implanted through an incision in the chest wall versus open heart surgery – New, less invasive technique provides cardiac surgeons with the ability to choose the optimal surgical method for their patients ABBOTT PARK, Ill., Jan. […]

ABBOTT ANNOUNCES ROBERT B. FORD TO SUCCEED MILES D. WHITE AS CHIEF EXECUTIVE OFFICER ON MARCH 31, 2020

– Mr. White will remain Executive Chairman of the Board – Mr. Ford has been elected to the Abbott Board ABBOTT PARK, Ill., Nov. 13, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Miles D. White will be stepping down as Chief Executive Officer on March 31, 2020, after a remarkable 21-year tenure, the second […]

Abbott Reports Third-Quarter 2019 Results

– Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent – Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity – Continues to strengthen portfolio with a steady cadence of new product approvals, reimbursement coverage and clinical data ABBOTT PARK, Ill., Oct. 16, 2019 /PRNewswire/ — Abbott […]

New Data Demonstrate Strong Outcomes for Abbott Device to Repair Leaky Tricuspid Heart Valves

– New data presented at TCT 2019 on Abbott’s TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints – Abbott’s TriClip tricuspid valve repair system design is based on the company’s market-leading MitraClip™ technology SAN FRANCISCO, Sept. 28, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced new […]